Study guide

3.1 Asthma, COPD & Airway Diseases

MRCPI in General Medicine Part I Written

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Strategy & Foundation

1.1 MRCPI Part I Format, Scoring & Standard-Setting 1.2 RCPI BST Curriculum & Single-Best-Answer Exam Strategy

2 Chapter 2: Cardiology & Vascular Medicine

2.1 Acute Coronary Syndromes & Stable Angina 2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies 2.3 Heart Failure & Valvular Heart Disease 2.4 Hypertension, Vascular & Pericardial Diseases

3 Chapter 3: Respiratory Medicine

3.1 Asthma, COPD & Airway Diseases 3.2 Pneumonia, Tuberculosis & Respiratory Infections 3.3 Interstitial Lung Disease & Pleural Disorders 3.4 Pulmonary Embolism, Pulmonary Hypertension & Sleep Apnoea

4 Chapter 4: Gastroenterology & Hepatology

4.1 Upper & Lower GI Disorders & Inflammatory Bowel Disease 4.2 Acute & Chronic Liver Disease 4.3 Pancreatitis, Biliary Tract & GI Bleeding 4.4 Malabsorption, GI Motility & Clinical Nutrition

5 Chapter 5: Nephrology & Acid-Base Disorders

5.1 Acute Kidney Injury & Glomerular Diseases 5.2 Chronic Kidney Disease & Renal Replacement Therapy 5.3 Electrolyte Imbalances & Acid-Base Disorders

6 Chapter 6: Endocrinology & Diabetes

6.1 Diabetes Mellitus & Metabolic Complications 6.2 Thyroid & Calcium Disorders 6.3 Adrenal, Pituitary & Endocrine Syndromes

7 Chapter 7: Rheumatology & Clinical Immunology

7.1 Inflammatory Arthritides 7.2 Systemic Autoimmune & Vasculitic Diseases 7.3 Metabolic Bone Disease & Clinical Immunology

8 Chapter 8: Haematology & Medical Oncology

8.1 Anaemias, Haemostasis & Thrombosis 8.2 Leukaemias, Lymphomas & Plasma Cell Disorders 8.3 Medical Oncology & Oncological Emergencies

9 Chapter 9: Neurology & Dermatology

9.1 Stroke & Cerebrovascular Diseases 9.2 Epilepsy, Headache & Movement Disorders 9.3 Neuromuscular & Peripheral Nerve Disorders 9.4 Cutaneous Manifestations of Systemic Disease

10 Chapter 10: Acute Medicine, Critical Care & Geriatrics

10.1 Acute Poisoning & Toxidromes 10.2 Sepsis, Shock & Resuscitation 10.3 Geriatric Syndromes, Frailty & Comprehensive Care

11 Chapter 11: Clinical Pharmacology & Therapeutics

11.1 Pharmacokinetics & Pharmacodynamics 11.2 High-Risk Drug Classes & Prescribing Safety 11.3 Adverse Drug Reactions & Drug Safety

12 Chapter 12: Basic Sciences, Biostatistics & Clinical Ethics

12.1 Applied Cardiovascular & Respiratory Physiology 12.2 Clinical Biochemistry, Molecular Genetics & Microbiology 12.3 Biostatistics, Evidence-Based Medicine & Ethics

3.1 Asthma, COPD & Airway Diseases

Key Takeaways Explain This Topic AI

Spirometric diagnosis of asthma requires bronchodilator reversibility demonstrating an FEV1 increase of >12% and >200 mL, or a peak expiratory flow (PEF) variability >20% over 2 weeks.

Life-threatening acute severe asthma is defined by any one of: PEF <33% predicted, SpO2 <92%, PaO2 <8.0 kPa, normal PaCO2 (4.6–6.0 kPa), silent chest, cyanosis, feeble respiratory effort, bradycardia, or confusion.

Post-bronchodilator FEV1/FVC ratio <0.70 establishes COPD, with GOLD staging categorizing airflow obstruction as GOLD 1 (FEV1 ≥80%), GOLD 2 (50–79%), GOLD 3 (30–49%), and GOLD 4 (<30% predicted).

Long-Term Oxygen Therapy (LTOT) is indicated in COPD when resting PaO2 is <7.3 kPa, or between 7.3–8.0 kPa in the presence of secondary polycythaemia (haematocrit >55%), pulmonary hypertension, or cor pulmonale.

High-resolution CT (HRCT) is the gold standard diagnostic for bronchiectasis, demonstrating an internal bronchial diameter greater than the adjacent pulmonary artery (bronchoarterial ratio >1.0, 'signet-ring sign') and lack of bronchial tapering.

Last updated: July 2026

Diagnostic Evaluation & Asthma Pathophysiology

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction, airway hyper-responsiveness, and bronchial wall remodeling. Symptoms include episodic dyspnoea, wheeze, chest tightness, and cough, typically worse at night or early morning.

Objective Spirometric Criteria

Bronchodilator Reversibility (BDR) : Post-bronchodilator spirometry following 400 µg inhaled salbutamol demonstrating an FEV1 increase of >12% and >200 mL relative to baseline confirms reversible airflow obstruction.

Peak Expiratory Flow (PEF) Variability : Diurnal PEF variability calculated as (Highest PEF - Lowest PEF) / Mean PEF > 20% over a 2-week monitoring period.

Fractional Ex exhaled Nitric Oxide (FeNO) : FeNO ≥50 ppb in adults indicates eosinophilic airway inflammation driven by T-helper 2 (Th2) cytokines (IL-4, IL-5, IL-13).

Airway Challenge Testing : Methacholine or histamine challenge testing revealing a Provocative Concentration causing a 20% drop in FEV1 (PC20) of <8 mg/mL establishes airway hyper-reactivity when baseline spirometry is normal.

Chronic Asthma Management (BTS/GINA Guidelines)

Under GINA 2024 guidance, management is divided into two tracks:

Track 1 (Preferred) : Uses low-dose ICS-formoterol as the anti-inflammatory reliever across all steps (as-needed in Steps 1–2; maintenance and reliever therapy [MART] in Steps 3–5).

Track 2 (Alternative) : Uses Short-Acting Beta-2 Agonists (SABA e.g., salbutamol) as reliever, paired with regular daily maintenance Inhaled Corticosteroid (ICS e.g., beclometasone, budesonide, fluticasone). Step-up therapy adds a Long-Acting Beta-2 Agonist (LABA e.g., salmeterol), Long-Acting Muscarinic Antagonist (LAMA e.g., tiotropium), or Leukotriene Receptor Antagonist (LTRA e.g., montelukast).

Exam Pearl : Biologic therapies targeting specific Th2 inflammatory pathways are indicated for severe refractory eosinophilic asthma:

Anti-IL-5 / Anti-IL-5Rα : Mepolizumab, Reslizumab, Benralizumab (indicated if blood eosinophils ≥300 cells/µL).

Anti-IL-4Rα : Dupilumab (inhibits IL-4 and IL-13 signaling).

Anti-IgE : Omalizumab (indicated for severe allergic asthma with elevated serum IgE).

Acute Severe & Life-Threatening Asthma: BTS Classification & Emergency Protocol

Acute asthma exacerbations require rapid clinical assessment and risk stratification based on British Thoracic Society (BTS) criteria.

  • Severity Category PEF (% Predicted or Best) Respiratory Rate Heart Rate Key Clinical Features
  • Moderate Exacerbation 50–75% <25 breaths/min <110 beats/min Normal speech, no signs of exhaustion
  • Acute Severe Asthma 33–50% ≥25 breaths/min ≥110 beats/min Inability to complete sentences in one breath

Life-Threatening Asthma <33% Any Any SpO2 <92%, PaO2 <8.0 kPa, normal/elevated PaCO2 (4.6–6.0 kPa), silent chest, cyanosis, feeble effort, bradycardia, hypotension, confusion

Near-Fatal Asthma <33% Any Any Elevated PaCO2 (>6.0 kPa) requiring mechanical ventilation with high inflation pressures

Critical Clinical Warning : A normal or elevated PaCO2 (4.6–6.0 kPa or >6.0 kPa) in a patient with severe asthma who is tachypnoeic represents respiratory muscle fatigue and impending respiratory arrest ! This is a medical emergency requiring immediate senior ITU escalation.

Stepwise Emergency Management Protocol

Oxygen Therapy : High-flow oxygen via non-rebreathe mask targeting SpO2 94–98% .

Inhaled Bronchodilators : Nebulised Salbutamol 5 mg driven by oxygen (6–8 L/min), repeated every 15–30 minutes, combined with nebulised Ipratropium bromide 0.5 mg 4–6 hourly.

Systemic Corticosteroids : Oral Prednisolone 40–50 mg daily (or IV Hydrocortisone 100 mg 6-hourly) continued for 5–7 days.

Intravenous Magnesium Sulphate : 1.2–2.0 g IV infusion over 20 minutes for patients with acute severe asthma not responding to initial inhaled therapy.

Intravenous Aminophylline / Salbutamol : Second-line IV bronchodilator infusions administered only in ITU/HDU settings with therapeutic drug monitoring.

Endotracheal Intubation & Mechanical Ventilation : Indicated for coma, respiratory arrest, worsening exhaustion with hypercapnia, or severe refractory acidosis.

COPD Staging & Maintenance Pharmacotherapy (GOLD Guidelines)

Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent, non-reversible airflow limitation due to airway (obstructive bronchitis) and/or alveolar abnormalities (emphysema), primarily triggered by tobacco smoke or biomass exposure.

Diagnostic Spirometry

A post-bronchodilator FEV1/FVC ratio <0.70 is mandatory to confirm persistent airflow obstruction.

Severity of airflow limitation is graded by post-bronchodilator FEV1 % predicted:

  • GOLD 1 (Mild) : FEV1 ≥80% predicted
  • GOLD 2 (Moderate) : FEV1 50–79% predicted
  • GOLD 3 (Severe) : FEV1 30–49% predicted
  • GOLD 4 (Very Severe) : FEV1 <30% predicted
  • GOLD ABE Assessment & Treatment Scheme

Exacerbation history and symptom burden (evaluated via mMRC dyspnoea scale or CAT score) guide maintenance therapy:

Group A (0–1 moderate exacerbations/year without hospital admission, mMRC 0–1): Initiate a single bronchodilator (LAMA or LABA).

Group B (0–1 moderate exacerbations/year, mMRC ≥2): Initiate LAMA + LABA combination therapy .

Group E (≥2 moderate exacerbations or ≥1 exacerbation leading to hospital admission): Initiate LAMA + LABA combination therapy . Add an Inhaled Corticosteroid (ICS) (triple therapy: LAMA + LABA + ICS) if blood eosinophil count is ≥300 cells/µL .

Long-Term Prophylaxis & Phosphodiesterase-4 Inhibitors

Azithromycin : 250 mg 3 times weekly may be prescribed for non-smokers with frequent exacerbations despite optimal inhaler therapy. Baseline ECG (to exclude QTc prolongation) and liver function tests are essential.

Roflumilast : Oral PDE-4 inhibitor indicated as add-on therapy in severe COPD (FEV1 <50%) associated with chronic bronchitis and frequent exacerbations.

Acute Exacerbations of COPD (AECOPD) & Non-Invasive Ventilation (NIV)

An acute exacerbation is defined by acute worsening of dyspnoea, cough, and/or sputum purulence and volume, commonly triggered by viral (rhinovirus, influenza) or bacterial (H. influenzae, S. pneumoniae, M. catarrhalis, Pseudomonas) infections.

Controlled Oxygen & Pharmacotherapy

Controlled Oxygen : Target SpO2 88–92% using a Venturi mask (24% or 28%) to prevent loss of hypoxic respiratory drive and severe hypercapnia resulting from ventilation-perfusion mismatching and Haldane effect.

Bronchodilators : Nebulised Salbutamol 2.5–5 mg and Ipratropium 0.5 mg driven by compressed air (not pure O2, to prevent hypercapnia).

Corticosteroids : Oral Prednisolone 30 mg PO daily for 5 days .

Antibiotics : Prescribed when sputum purulence is present alongside increased dyspnoea or sputum volume. First-line choices include Amoxicillin 500 mg TDS, Doxycycline 200 mg stat then 100 mg OD, or Clarithromycin 500 mg BD for 5 days.

Non-Invasive Ventilation (NIV / BiPAP)

NIV provides bilevel positive airway pressure (BiPAP) and is the standard of care for acute decompensated type II respiratory failure.

Indications : Acute hypercapnic respiratory failure with pH 7.25–7.35 and PaCO2 >6.0 kPa despite maximal medical therapy.

Initial Settings : Inspiratory Positive Airway Pressure (IPAP) 10–12 cmH2O ; Expiratory Positive Airway Pressure (EPAP) 4–5 cmH2O ; titrated to achieve target SpO2 88–92% and resolve respiratory acidosis.

Contraindications : Facial trauma/burns, fixed upper airway obstruction, severe vomiting, bowel obstruction, undrained pneumothorax, or inability to protect airway.

  • Long-Term Oxygen Therapy (LTOT) & Alpha-1 Antitrypsin Deficiency
  • Long-Term Oxygen Therapy (LTOT) Criteria

LTOT improves survival in COPD patients with severe chronic hypoxaemia. Assessment must be performed in a stable state at least 5 weeks post-exacerbation on optimal medical therapy.

Primary Indication : Resting room air PaO2 <7.3 kPa .

Secondary Indication : Resting room air PaO2 between 7.3 and 8.0 kPa PLUS evidence of:

  • Secondary polycythaemia (haematocrit >55% ),
  • Clinical or echocardiographic pulmonary hypertension, or

Peripheral oedema / cor pulmonale.

Operational Requirements : Administered via nasal cannulae for ≥15 hours per day (including overnight). Patients MUST be non-smokers due to catastrophic domestic fire risk.

Bronchiectasis

Bronchiectasis involves permanent abnormal dilation of the bronchi resulting from chronic inflammation and impaired mucociliary clearance.

Diagnostic Gold Standard : High-Resolution CT (HRCT) demonstrating an internal bronchial diameter >1.0 times the diameter of the adjacent pulmonary artery ( bronchoarterial ratio >1.0 , "signet-ring sign") and failure of bronchial tapering toward the periphery.

Microbiology & Management : Sputum colonisation with Pseudomonas aeruginosa portends accelerated FEV1 decline and increased hospitalisations. Treatment includes regular chest physiotherapy (active cycle of breathing techniques), hypertonic saline nebulisers (3–7%), and prompt antibiotic therapy (oral Ciprofloxacin 750 mg BD for P. aeruginosa).

Alpha-1 Antitrypsin (A1AT) Deficiency

Genetics : Autosomal co-dominant disorder caused by mutations in the SERPINA1 gene on chromosome 14. Normal allele is PiM; severe deficiency phenotype is PiZZ (serum A1AT levels <11 µmol/L).

Pathology : Lack of protective neutrophil elastase inhibition causes panacinar emphysema classically localized to the lower lobes of the lungs in young non-smokers (30–40 years).

Extrapulmonary Manifestations : Accumulation of misfolded mutant protein in hepatocytes causes neonatal cholestasis, juvenile cirrhosis, and hepatocellular carcinoma.